Selected research
Industry Research
Next-Generation Tumor Genetic Testing Industry Research Report 2026
Market perspective
The global Next-Generation Tumor Genetic Testing market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Next-Generation Tumor Genetic Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Next-Generation Tumor Genetic Testing market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Next-Generation Tumor Genetic Testing market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Next-Generation Tumor Genetic Testing include Devyser, Agendia, Illumina, Personal Genome Diagnostics, Veracyte, Pacific Biosciences of California, Qiagen, Agilent Technologies and Natera, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Next-Generation Tumor Genetic Testing market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Next-Generation Tumor Genetic Testing.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Next-Generation Tumor Genetic Testing Market by Company
Devyser
Agendia
Illumina
Personal Genome Diagnostics
Veracyte
Pacific Biosciences of California
Qiagen
Agilent Technologies
Natera
Bio Rad Laboratories
Myriad Genetics
Next-Generation Tumor Genetic Testing Segment by Type
Fluorescence In Situ Hybridization
Polymerase Chain Reaction
Microarray Technology
Serum Proteomics
Nucleic Acid Sequencing
Next-Generation Tumor Genetic Testing Segment by Application
Hospitals
Speciality Clinics
Research Institutes
Diagnostics Laboratories
Biopharmaceutical Companies
Next-Generation Tumor Genetic Testing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Next-Generation Tumor Genetic Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Next-Generation Tumor Genetic Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Next-Generation Tumor Genetic Testing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Next-Generation Tumor Genetic Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Fluorescence In Situ Hybridization
- Polymerase Chain Reaction
- Microarray Technology
- Serum Proteomics
- Nucleic Acid Sequencing
Applications
- Hospitals
- Speciality Clinics
- Research Institutes
- Diagnostics Laboratories
- Biopharmaceutical Companies
Companies covered
- Devyser
- Agendia
- Illumina
- Personal Genome Diagnostics
- Veracyte
- Pacific Biosciences of California
- Qiagen
- Agilent Technologies
- Natera
- Bio Rad Laboratories
- Myriad Genetics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Next-Generation Tumor Genetic Testing by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Fluorescence In Situ Hybridization
- 2.2.3 Polymerase Chain Reaction
- 2.2.4 Microarray Technology
- 2.2.5 Serum Proteomics
- 2.2.6 Nucleic Acid Sequencing
- 2.3 Next-Generation Tumor Genetic Testing by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospitals
- 2.3.3 Speciality Clinics
- 2.3.4 Research Institutes
- 2.3.5 Diagnostics Laboratories
- 2.3.6 Biopharmaceutical Companies
- 2.4 Assumptions and Limitations
3 Next-Generation Tumor Genetic Testing Breakdown Data by Type
- 3.1 Global Next-Generation Tumor Genetic Testing Historic Market Size by Type (2021-2026)
- 3.2 Global Next-Generation Tumor Genetic Testing Forecasted Market Size by Type (2027-2032)
4 Next-Generation Tumor Genetic Testing Breakdown Data by Application
- 4.1 Global Next-Generation Tumor Genetic Testing Historic Market Size by Application (2021-2026)
- 4.2 Global Next-Generation Tumor Genetic Testing Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Next-Generation Tumor Genetic Testing Market Perspective (2021-2032)
- 5.2 Global Next-Generation Tumor Genetic Testing Growth Trends by Region
- 5.2.1 Global Next-Generation Tumor Genetic Testing Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Next-Generation Tumor Genetic Testing Historic Market Size by Region (2021-2026)
- 5.2.3 Next-Generation Tumor Genetic Testing Forecasted Market Size by Region (2027-2032)
- 5.3 Next-Generation Tumor Genetic Testing Market Dynamics
- 5.3.1 Next-Generation Tumor Genetic Testing Industry Trends
- 5.3.2 Next-Generation Tumor Genetic Testing Market Drivers
- 5.3.3 Next-Generation Tumor Genetic Testing Market Challenges
- 5.3.4 Next-Generation Tumor Genetic Testing Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Next-Generation Tumor Genetic Testing Players by Revenue
- 6.1.1 Global Top Next-Generation Tumor Genetic Testing Players by Revenue (2021-2026)
- 6.1.2 Global Next-Generation Tumor Genetic Testing Revenue Market Share by Players (2021-2026)
- 6.2 Global Next-Generation Tumor Genetic Testing Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Next-Generation Tumor Genetic Testing Head Office and Area Served
- 6.4 Global Next-Generation Tumor Genetic Testing Players, Product Type & Application
- 6.5 Global Next-Generation Tumor Genetic Testing Manufacturers Established Date
- 6.6 Global Next-Generation Tumor Genetic Testing Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Next-Generation Tumor Genetic Testing Market Size (2021-2032)
- 7.2 North America Next-Generation Tumor Genetic Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Next-Generation Tumor Genetic Testing Market Size by Country (2021-2026)
- 7.4 North America Next-Generation Tumor Genetic Testing Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Next-Generation Tumor Genetic Testing Market Size (2021-2032)
- 8.2 Europe Next-Generation Tumor Genetic Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Next-Generation Tumor Genetic Testing Market Size by Country (2021-2026)
- 8.4 Europe Next-Generation Tumor Genetic Testing Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Next-Generation Tumor Genetic Testing Market Size (2021-2032)
- 9.2 Asia-Pacific Next-Generation Tumor Genetic Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Next-Generation Tumor Genetic Testing Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Next-Generation Tumor Genetic Testing Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Next-Generation Tumor Genetic Testing Market Size (2021-2032)
- 10.2 South America Next-Generation Tumor Genetic Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Next-Generation Tumor Genetic Testing Market Size by Country (2021-2026)
- 10.4 South America Next-Generation Tumor Genetic Testing Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Next-Generation Tumor Genetic Testing Market Size (2021-2032)
- 11.2 Middle East & Africa Next-Generation Tumor Genetic Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Next-Generation Tumor Genetic Testing Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Next-Generation Tumor Genetic Testing Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Devyser
- 12.1.1 Devyser Company Information
- 12.1.2 Devyser Business Overview
- 12.1.3 Devyser Revenue in Next-Generation Tumor Genetic Testing Business (2021-2026)
- 12.1.4 Devyser Next-Generation Tumor Genetic Testing Product Portfolio
- 12.1.5 Devyser Recent Developments
- 12.2 Agendia
- 12.2.1 Agendia Company Information
- 12.2.2 Agendia Business Overview
- 12.2.3 Agendia Revenue in Next-Generation Tumor Genetic Testing Business (2021-2026)
- 12.2.4 Agendia Next-Generation Tumor Genetic Testing Product Portfolio
- 12.2.5 Agendia Recent Developments
- 12.3 Illumina
- 12.3.1 Illumina Company Information
- 12.3.2 Illumina Business Overview
- 12.3.3 Illumina Revenue in Next-Generation Tumor Genetic Testing Business (2021-2026)
- 12.3.4 Illumina Next-Generation Tumor Genetic Testing Product Portfolio
- 12.3.5 Illumina Recent Developments
- 12.4 Personal Genome Diagnostics
- 12.4.1 Personal Genome Diagnostics Company Information
- 12.4.2 Personal Genome Diagnostics Business Overview
- 12.4.3 Personal Genome Diagnostics Revenue in Next-Generation Tumor Genetic Testing Business (2021-2026)
- 12.4.4 Personal Genome Diagnostics Next-Generation Tumor Genetic Testing Product Portfolio
- 12.4.5 Personal Genome Diagnostics Recent Developments
- 12.5 Veracyte
- 12.5.1 Veracyte Company Information
- 12.5.2 Veracyte Business Overview
- 12.5.3 Veracyte Revenue in Next-Generation Tumor Genetic Testing Business (2021-2026)
- 12.5.4 Veracyte Next-Generation Tumor Genetic Testing Product Portfolio
- 12.5.5 Veracyte Recent Developments
- 12.6 Pacific Biosciences of California
- 12.6.1 Pacific Biosciences of California Company Information
- 12.6.2 Pacific Biosciences of California Business Overview
- 12.6.3 Pacific Biosciences of California Revenue in Next-Generation Tumor Genetic Testing Business (2021-2026)
- 12.6.4 Pacific Biosciences of California Next-Generation Tumor Genetic Testing Product Portfolio
- 12.6.5 Pacific Biosciences of California Recent Developments
- 12.7 Qiagen
- 12.7.1 Qiagen Company Information
- 12.7.2 Qiagen Business Overview
- 12.7.3 Qiagen Revenue in Next-Generation Tumor Genetic Testing Business (2021-2026)
- 12.7.4 Qiagen Next-Generation Tumor Genetic Testing Product Portfolio
- 12.7.5 Qiagen Recent Developments
- 12.8 Agilent Technologies
- 12.8.1 Agilent Technologies Company Information
- 12.8.2 Agilent Technologies Business Overview
- 12.8.3 Agilent Technologies Revenue in Next-Generation Tumor Genetic Testing Business (2021-2026)
- 12.8.4 Agilent Technologies Next-Generation Tumor Genetic Testing Product Portfolio
- 12.8.5 Agilent Technologies Recent Developments
- 12.9 Natera
- 12.9.1 Natera Company Information
- 12.9.2 Natera Business Overview
- 12.9.3 Natera Revenue in Next-Generation Tumor Genetic Testing Business (2021-2026)
- 12.9.4 Natera Next-Generation Tumor Genetic Testing Product Portfolio
- 12.9.5 Natera Recent Developments
- 12.10 Bio Rad Laboratories
- 12.10.1 Bio Rad Laboratories Company Information
- 12.10.2 Bio Rad Laboratories Business Overview
- 12.10.3 Bio Rad Laboratories Revenue in Next-Generation Tumor Genetic Testing Business (2021-2026)
- 12.10.4 Bio Rad Laboratories Next-Generation Tumor Genetic Testing Product Portfolio
- 12.10.5 Bio Rad Laboratories Recent Developments
- 12.11 Myriad Genetics
- 12.11.1 Myriad Genetics Company Information
- 12.11.2 Myriad Genetics Business Overview
- 12.11.3 Myriad Genetics Revenue in Next-Generation Tumor Genetic Testing Business (2021-2026)
- 12.11.4 Myriad Genetics Next-Generation Tumor Genetic Testing Product Portfolio
- 12.11.5 Myriad Genetics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst